Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press5910.17650/1994-4098-2013-0-3-4-60-66MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕHER-2-positive metastatic breast cancer: new possibilities for therapyHER-2-позитивный метастатический рак молочной железы: новые возможности терапииArtamonovaE. V.АртамоноваЕ. В.
Russian Federation
artamonovae@mail.ruManzyukL. V.МанзюкЛ. В.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва220920133-4606622072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/59

This article is devoted to modern approaches in HER-2-positive metastatic breast cancer therapy. Recently treatment algorithm for this type of cancer included trastuzumab plus cytostatic in first line, continuation of trastuzumab with another chemotherapy regimen in second line, further switch to lapatinib and eventual return to trastuzumab after progression. Nowadays our options are broader owing to new anti-HER-2 agents which are pertruzumab and T-DM1. Now the most effective therapy regimen in first line is double HER-2 blockade (trastuzumab + pertuzumab) in combination with docetaxel. Benefit of new agent T-DM1 versus combination of lapatinib and capecitabin is proved in patients progressed on trastuzumab and taxanes. T-DM1 also showed high efficacy as salvage therapy in intensively pretreated patients with meta- static HER-2-positive breast cancer who progressed on taxanes, trastuzumab and lapatinib.

metastatic breast canceranti-HER-2-therapytrastuzumabpertuzumabT-DM1метастатический рак молочной железыанти-HER-2 терапиятрастузумаблапатинибпертузумабТ-ДМ11. Masuda H., Baggerly K. A., Wang Y. et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among mo- lecular subtypes of triple-negative breast can- cer. J Clin Oncol 2013;31(Suppl); abstr. 1005.Masuda H., Baggerly K. A., Wang Y. et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among mo- lecular subtypes of triple-negative breast can- cer. J Clin Oncol 2013;31(Suppl); abstr. 1005.2. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235(4785): 177–82.Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235(4785): 177–82.3. Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 1989;244(4905):707–12.Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 1989;244(4905):707–12.4. Hudis C.A. Trastuzumab-mechanism of ac- tion and use in clinical practice. N Engl J Med 2007;357(1):39–51.Hudis C.A. Trastuzumab-mechanism of ac- tion and use in clinical practice. N Engl J Med 2007;357(1):39–51.5. Perou C.M. Molecular Stratification of Tri- ple-Negative Breast Cancer The Oncologist 2011;16(Suppl 1):61–70.Perou C.M. Molecular Stratification of Tri- ple-Negative Breast Cancer The Oncologist 2011;16(Suppl 1):61–70.6. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal anti- body against HER-2 for metastatic breast can- cer that overexpresses HER-2. N Engl J Med 2001;334(11):783–92.Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal anti- body against HER-2 for metastatic breast can- cer that overexpresses HER-2. N Engl J Med 2001;334(11):783–92.7. Keefe D.L. Trastuzumab-associated cardio- toxicity. Cancer 2002;95(7):1592–600.Keefe D.L. Trastuzumab-associated cardio- toxicity. Cancer 2002;95(7):1592–600.8. Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215–21.Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215–21.9. Cortazar P., Johnson J.R., Justice R., Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. Proc ASCO 2008 (J Clin Oncol 2008);26(Suppl 15); abstr. 1013.Cortazar P., Johnson J.R., Justice R., Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. Proc ASCO 2008 (J Clin Oncol 2008);26(Suppl 15); abstr. 1013.10. Peacock N.W., Infante J.R., Yardley D.A. et al. Phase II trial of weekly docetaxel, vinorelbine and trastuzumab in the first-line treatment of patients (pts) with HER-2-posi- tive metastatic breast cancer (MBC). Proc ASCO 2008 (J Clin Oncol 2008);26:49S; abstr. 1032.Peacock N.W., Infante J.R., Yardley D.A. et al. Phase II trial of weekly docetaxel, vinorelbine and trastuzumab in the first-line treatment of patients (pts) with HER-2-posi- tive metastatic breast cancer (MBC). Proc ASCO 2008 (J Clin Oncol 2008);26:49S; abstr. 1032.11. Kash J., Barlow W.E., Albain K.S. et al. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2-positive stage IV breast cancer. Proc ASCO 2008 (J Clin Oncol 2008);26:49S; abstr. 1033.Kash J., Barlow W.E., Albain K.S. et al. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2-positive stage IV breast cancer. Proc ASCO 2008 (J Clin Oncol 2008);26:49S; abstr. 1033.12. Gelmon K.A., Boyle F., Kaufman B. et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER-2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012;30(Suppl); abstr. LBA671.Gelmon K.A., Boyle F., Kaufman B. et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER-2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012;30(Suppl); abstr. LBA671.13. Marty M., Cognetti F., Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth fac- tor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J ClinMarty M., Cognetti F., Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth fac- tor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J ClinOncol 2005;23(19):4265–74.14. Robert N., Leyland-Jones B., Asmar L. et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with tras- tuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast can- cer. J Clin Oncol 2006;24(18):2786–92.Robert N., Leyland-Jones B., Asmar L. et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with tras- tuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast can- cer. J Clin Oncol 2006;24(18):2786–92.15. Pegram M., Forbes J., Pienkowski T. et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER-2 amplified metastaticPegram M., Forbes J., Pienkowski T. et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER-2 amplified metastatic